Merck & Company, Inc. Press Releases

MRK 
$48.85
*  
0.68
1.37%
Get MRK Alerts
*Delayed - data as of Feb. 11, 2016  -  Find a broker to begin trading MRK now
Exchange: NYSE
Industry: Health Care
Community Rating:
View:    MRK Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing

FDA Approves Merck’s Single-Dose EMEND® (fosaprepitant dimeglumine) for Injection, in Combination with Other Antiemetic Agents, for the Prevention of Delayed Nausea and Vomiting in Adults Receiving Moderately Emetogenic Chemotherapy (MEC)
2/4/2016 8:00:00 AM - Business Wire
▼-2.08 % Price Change since this news event. The Volume Ratio is 1.37.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck Announces Fourth-Quarter and Full-Year 2015 Financial Results
2/3/2016 6:45:00 AM - Business Wire
▼-0.51 % Price Change since this news event. The Volume Ratio is 1.46.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Merck Receives FDA Approval of ZEPATIER™ (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection in Adults Following Priority Review
1/28/2016 7:01:00 PM - PR Newswire
▼-2.50 % Price Change since this news event. The Volume Ratio is 1.48.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


A Small-Cap Biotech With Big Ideas for Acute Infections and Cancers: Cellceutix's Leo Ehrlich and Dr. Daniel Jorgensen
1/28/2016 3:50:00 PM - Market Wire
▼-0.65 % Price Change since this news event. The Volume Ratio is 3.47.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck Announces FDA Acceptance of Biologics License Application for Bezlotoxumab, an Investigational Antitoxin for Prevention of Clostridium Difficile Infection Recurrence
1/27/2016 8:30:00 AM - Business Wire
▼-3.61 % Price Change since this news event. The Volume Ratio is 1.83.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Data for KEYTRUDA® (pembrolizumab) in a Range of Gastrointestinal Cancers to be Presented at 2016 Gastrointestinal Cancers Symposium
1/19/2016 10:00:00 AM - Business Wire
▼-5.09 % Price Change since this news event. The Volume Ratio is 0.81.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Nordex Explosives Ltd. Announces Loan
1/15/2016 9:27:00 AM - Market Wire




Merck Resolves Previously Disclosed Securities Class Action Lawsuit Related to Vioxx
1/15/2016 7:00:00 AM - Business Wire
▼-4.22 % Price Change since this news event. The Volume Ratio is 1.2.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck Acquires IOmet Pharma and Expands Immuno-Oncology Development Program
1/11/2016 4:08:00 PM - Business Wire
▼-4.68 % Price Change since this news event. The Volume Ratio is 0.96.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck to Present at the 34th Annual J.P. Morgan Healthcare Conference
1/8/2016 8:00:00 AM - Business Wire
▼-6.51 % Price Change since this news event. The Volume Ratio is 1.32.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Merck to Hold Fourth-Quarter and Full-Year 2015 Sales and Earnings Conference Call on February 3
1/5/2016 8:00:00 AM - Business Wire
▼-7.08 % Price Change since this news event. The Volume Ratio is 1.5.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Merck to Present at Goldman Sachs Healthcare CEOs Unscripted: A View from the Top
1/4/2016 8:00:00 AM - Business Wire
▼-7.52 % Price Change since this news event. The Volume Ratio is 3.15.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


World Health Organization to Review Merck’s Investigational Ebola Vaccine for Emergency Use Assessment and Listing
12/23/2015 8:30:00 AM - Business Wire
▼-6.24 % Price Change since this news event. The Volume Ratio is 0.63.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck’s KEYTRUDA® (pembrolizumab) Significantly Improves Survival Compared to Chemotherapy in Previously-Treated Patients with Non-Small Cell Lung Cancer Whose Tumors Express Any Level of PD-L1
12/19/2015 10:55:00 AM - Business Wire
▼-5.26 % Price Change since this news event. The Volume Ratio is 0.98.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Advanced Melanoma
12/18/2015 4:05:00 PM - Business Wire
▼-5.40 % Price Change since this news event. The Volume Ratio is 1.26.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




MSD Provides Update on European Medicines Agency Marketing Authorisation Application for Investigational Chronic Hepatitis C Therapy Elbasvir/Grazoprevir
12/18/2015 8:00:00 AM - Business Wire
▼-6.88 % Price Change since this news event. The Volume Ratio is 1.75.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck Provides Update on European Medicines Agency Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Elbasvir/Grazoprevir
12/18/2015 8:00:00 AM - Business Wire
▼-6.88 % Price Change since this news event. The Volume Ratio is 1.75.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


FDA Approves Expanded Age Indication for GARDASIL® 9 in Males
12/15/2015 5:07:00 PM - Business Wire
▼-7.64 % Price Change since this news event. The Volume Ratio is 0.95.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day





Learn more by visiting our FAQ page